HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 279, Issue 52, 53907-53914, December 24, 2004

This Article Full Text Full Text (PDF) All Versions of this Article: 279/52/53907    most recent M407888200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shahied, L. S. Articles by Weiner, L. M. Search for Related Content PubMed PubMed Citation Articles by Shahied, L. S. Articles by Weiner, L. M. Social Bookmarking                      What's this?

Bispecific Minibodies Targeting HER2/neu and CD16 Exhibit Improved Tumor Lysis When Placed in a Divalent Tumor Antigen Binding Format^*

Lillian S. Shahied, Yong Tang, R. Katherine Alpaugh, Robert Somer, Dana Greenspon, and Louis M. Weiner

From the Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111

Unconjugated monoclonal antibodies have emerged as important therapeutic agents for selected malignancies. One mechanism by which antibodies can exert cytotoxic effects is antibody-dependent cellular cytotoxicity (ADCC). In an effort to increase the efficiency of ADCC at tumor sites, we have focused on the construction of bispecific antibodies specific for the tumor antigen HER2/neu and the FcRIII-activating receptor (CD16) found on NK cells, mononuclear phagocytes, and neutrophils. Here, we describe the production of bispecific minibodies in two distinct binding formats. The parent minibody was constructed such that the IgG1 C_H3 constant domain serves as the oligomerization domain and is attached to an anti-CD16 and an anti-HER2/ neu single-chain Fv via 19- and 29-amino acid linkers, respectively. This molecule can be expressed in mammalian cells from a dicistronic vector and has been purified using sequential affinity purification techniques. Analysis by surface plasmon resonance shows that the bispecific minibody can bind to HER2/neu and CD16, both individually and simultaneously. Furthermore, cytotoxicity studies show that the minibody can induce significant tumor cell lysis at a concentration as low as 20 nM. A trimeric, bispecific minibody (TriBi) that binds dimerically to HER2/neu and monomerically to CD16 induces equivalent cytotoxicity at lower antibody concentrations than either the parent minibody or the corresponding single-chain dimer. Both minibody constructs are stable in mouse and human serum for up to 72 h at 37 °C. These minibodies have the potential to target solid tumors and promote tumor lysis by natural killer cells and mononuclear phagocytes.

Received for publication, July 13, 2004 , and in revised form, October 5, 2004.

^* This work was supported by National Institutes of Health Grants CA07125, P32 CA009035 (to L. S. S.), and CA50633 (to L. M. W.), an appropriation from the Commonwealth of Pennsylvania, and funds from the Frank Strick Foundation and the Bernard A. and Rebecca S. Bernard Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Present address: Centocor, Inc., 145 King of Prussia Rd., Radnor, PA 19087.

To whom correspondence should be addressed: Fox Chase Cancer Center, 333 Cottman Ave., Philadelphia, PA 19111. Tel.: 215-728-2480; Fax: 215-728-5339; E-mail: Louis.Weiner{at}fccc.edu.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. Asano, Y. Sone, K. Ikoma, H. Hayashi, T. Nakanishi, M. Umetsu, Y. Katayose, M. Unno, T. Kudo, and I. Kumagai Preferential heterodimerization of a bispecific diabody based on a humanized anti-EGFR antibody 528 Protein Eng. Des. Sel., October 1, 2008; 21(10): 597 - 603. [Abstract] [Full Text] [PDF]

				R. Asano, Y. Watanabe, H. Kawaguchi, H. Fukazawa, T. Nakanishi, M. Umetsu, H. Hayashi, Y. Katayose, M. Unno, T. Kudo, et al. Highly Effective Recombinant Format of a Humanized IgG-like Bispecific Antibody for Cancer Immunotherapy with Retargeting of Lymphocytes to Tumor Cells J. Biol. Chem., September 21, 2007; 282(38): 27659 - 27665. [Abstract] [Full Text] [PDF]

				Y. Tang, J. Lou, R. K. Alpaugh, M. K. Robinson, J. D. Marks, and L. M. Weiner Regulation of Antibody-Dependent Cellular Cytotoxicity by IgG Intrinsic and Apparent Affinity for Target Antigen J. Immunol., September 1, 2007; 179(5): 2815 - 2823. [Abstract] [Full Text] [PDF]

				N. Ahmed, M. Ratnayake, B. Savoldo, L. Perlaky, G. Dotti, W. S. Wels, M. B. Bhattacharjee, R. J. Gilbertson, H. D. Shine, H. L. Weiss, et al. Regression of Experimental Medulloblastoma following Transfer of HER2-Specific T Cells Cancer Res., June 15, 2007; 67(12): 5957 - 5964. [Abstract] [Full Text] [PDF]